Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver-unspecific Naranjo scale precise enough to ascertain causality?

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 567-582

  Teschke, Rolf ^a   Schmidt Taenzer, Wolfgang ^a   Wolff, Albrecht ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Black cohosh hepatotoxicity; Drug induced liver injury; Herbal hepatotoxicity; Herbs induced liver injury; Naranjo scale

Indexed keywords

ALANINE AMINOTRANSFERASE; CIMICIFUGA RACEMOSA EXTRACT; FLUOXETINE; GAMMA GLUTAMYLTRANSFERASE; HERBACEOUS AGENT; INTERFERON; ROSUVASTATIN;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; CAUSAL ATTRIBUTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONFOUNDING VARIABLE; COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; FEMALE; HEPATOBILIARY DISEASE; HUMAN; LIVER DISEASE; LIVER TOXICITY; MENOPAUSE; NARANJO SCALE; PRIORITY JOURNAL; RATING SCALE; RHABDOMYOLYSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ALGORITHMS; CIMICIFUGA; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MIDDLE AGED; PLANT EXTRACTS;

EID: 79959400420     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2127     Document Type: Article

References (39)

1. Björnsson E. The natural history of drug-induced liver injury. Semin Liver Dis 2009; 24: 357-363.
2. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 24: 373-382.
3. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol 2009; 5: 843-860.
4. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30: 1270-1279.
5. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
6. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
7. García-Cortés M, Lucena MI, Andrade RJ, Camargo R, Alcántara R. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother 2004; 38: 1540-1541.
8. García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008; 27: 780-789.
9. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-766.
10. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al.; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-1183.
11. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.; Drug-Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
12. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470.
13. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonachini M, et al.; US Drug-induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-2126.
14. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al.; Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
15. Andrade RJ, Lucena MI, Kaplowitz N, García-Muñoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: long term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-1588.
16. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009; 8: 184-195.
17. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany). Rejection of drug risks, step II. As related to: kava-kava (piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. June 14, 2002. [9 August 2010].
18. World Health Organization. Assessments of Risk of Hepatotoxicity with Kava Products. WHO Document Production Services: Geneva, 2007.
19. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193.
20. Teschke R. Kava hepatotoxicity-a clinical review. Ann Hepatol 2010; 9: 251-265.
21. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, et al. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-484.
22. EMEA. Assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, root). [9 August 2010].
23. Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008; 15: 628-638.
24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
25. Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liver Dis 2009; 41 891-901.
26. Teschke R, Fuchs J, Bahre R, Genthner A, Wolff A. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther 2010; 35: 545-563.
27. Health Canada. Black cohosh products and liver toxicity: update. Canadian Adverse Reaction Newsletter 2010; 20: 1-3. [9 August 2010].
28. Thomsen M, Vitetta L, Sali A, Schmidt M. Letter to the editor: acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2004; 180: 598-599.
29. Cumming FJ, Kelly L. Response to letter to the editor. Med J Aust 2004; 180: 599-600.
30. Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. New Zeal Med J 2008; 121: 1283. [9 August 2010].
31. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifuga racemosa rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72-84.
32. Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009; 16: 956-965.
33. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause 2003; 10: 299-313.
34. Gori L, Firenzuoli F. Is black cohosh a hepatotoxic medicinal herb? Forsch Komplementärmed 2007; 17: 109-110.
35. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol 2008; 199: 455-466.
36. Firenzuoli F, Gori L, Roberti di Sarsina P. Black cohosh hepatic safety: follow-up of 107 patients consuming a special Cimicifuga racemosa rhizome herbal extract and review of literature. Evid-Based Compl Alt 2008. DOI: 10.1093/ecam/nen009
37. Naser B, Schnitker J, Minkin MJ, Garcia de Arriba S, Noltke KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause 2011; 18: in press. DOI: 10.1097/gme.0b013e181fcb2a6
38. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharm 2011; 59: 1-7.
39. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010; 105: 1561-1566.